三元基因(837344) - 2024 Q1 - 季度财报

Financial Performance - Operating revenue for Q1 2024 reached CNY 47,952,373.12, representing a 39.49% increase year-over-year [10]. - Net profit attributable to shareholders for Q1 2024 was CNY 1,928,398.18, up 9.87% from the same period last year [10]. - The company's gross profit margin increased, with operating costs rising by 41.20% to CNY 9,185,324.05 due to higher sales volume [12]. - The company’s basic earnings per share doubled to CNY 0.02 from CNY 0.01 in the previous year [10]. - Total revenue for Q1 2024 reached ¥47,952,373.12, a significant increase of 39.6% compared to ¥34,376,162.80 in Q1 2023 [43]. - Operating profit for Q1 2024 was ¥2,240,369.16, slightly up from ¥2,202,164.55 in Q1 2023, indicating a stable performance [44]. - Net profit for Q1 2024 was ¥1,928,398.18, representing a 9.8% increase from ¥1,755,211.84 in Q1 2023 [44]. - Earnings per share for Q1 2024 were ¥0.02, consistent with Q1 2023 [45]. Cash Flow and Assets - The net cash flow from operating activities was CNY 15,256,581.97, a significant increase of 233.62% compared to Q1 2023 [10]. - Operating cash inflow for Q1 2024 was CNY 66,423,147.36, a significant increase from CNY 36,843,520.22 in Q1 2023, representing an increase of 80.2% [48]. - Cash outflow for investment activities decreased to CNY 46,173,069.57 in Q1 2024 from CNY 108,461,515.10 in Q1 2023, indicating a reduction of 57.4% [49]. - Cash inflow from financing activities was CNY 32,523,874.00 in Q1 2024, down from CNY 77,700,006.08 in Q1 2023, a decrease of 58.2% [49]. - The ending cash and cash equivalents balance for Q1 2024 was CNY 157,128,684.11, down from CNY 180,526,369.49 in Q1 2023 [49]. - Total current assets decreased to CNY 276,537,250.04 from CNY 306,918,274.64, a decline of approximately 9.9% [37]. - Cash and cash equivalents decreased to CNY 157,128,684.11 from CNY 177,507,670.01, a decrease of about 11.5% [37]. - Accounts receivable decreased to CNY 70,872,074.34 from CNY 83,602,734.13, representing a decline of approximately 15.3% [37]. - Total non-current assets increased to CNY 944,751,490.26 from CNY 928,255,592.19, an increase of about 1.5% [38]. - Total assets as of March 31, 2024, were CNY 1,221,288,740.30, a decrease of 1.12% compared to the end of 2023 [10]. Liabilities and Equity - The asset-liability ratio for the consolidated entity decreased to 49.75% from 50.54% year-over-year [10]. - Total liabilities decreased to CNY 607,605,085.13 from CNY 624,235,299.84, a reduction of approximately 2.6% [39]. - Total equity increased to CNY 613,683,655.17 from CNY 610,938,566.99, an increase of about 0.4% [39]. - Long-term borrowings increased to CNY 438,250,530.75 from CNY 414,229,240.81, an increase of approximately 5.8% [39]. - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of the total shares [19]. Research and Development - The company has completed the Phase III clinical trial for interferon α1b nebulization treatment for RSV pneumonia in children, showing significant efficacy and safety, with a reduction in clinical symptom duration by nearly one day within 72 hours of treatment [28]. - The company has initiated a Phase III clinical trial for interferon α1b in the prevention and treatment of COVID-19, with 400 patients enrolled across three newly approved clinical centers [29]. - The predictive accuracy for E antigen seroconversion and S antigen negativity in the new PEG-integrated interferon clinical trial has reached 84% and 75%, respectively [30]. - The company has improved the expansion process of γδT cells from 450 times to 16,000 times, significantly increasing the yield of cell preparations for tumor immunotherapy [31]. - Research and development expenses for Q1 2024 were ¥2,924,856.44, up from ¥2,518,540.70 in Q1 2023, highlighting a focus on innovation [43]. Operational Developments - The new intelligent production and R&D base has been recognized as a key project by the Beijing government, with an annual production capacity exceeding 100 million units across various dosage forms [32]. - The new facility incorporates advanced technologies such as industrial internet and big data analysis, aiming to enhance operational efficiency and reduce costs [33]. - The construction of the new facility has entered the completion and acceptance phase, with various approvals obtained from local authorities [34]. Commitments and Legal Matters - There are no significant changes in the disclosed commitments, and all commitments have been strictly adhered to [24]. - There are no litigation or arbitration matters reported during the reporting period [22]. - The company has not experienced any significant changes in shareholder equity or major transactions during the reporting period [22].